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OBJECTIVES We sought to study the effect of low-dose folic acid supplementation or optimization of
dietary folate intake on plasma homocysteine and endothelial function in healthy adults.
BACKGROUND Elevated homocysteine is associated with cardiovascular disease, but it is not known whether
this relationship is causal. Individuals homozygous (TT) for the C677T mutation in the
methylenetetrahydrofolate reductase (MTHFR) gene (12% of the population) have
increased homocysteine levels, particularly in association with suboptimal folate intake.
METHODS Healthy subjects (n  126; 42 of each MTHFR genotype) were included in this cross-over
study of three interventions of four months each: 1) placebo plus natural diet; 2) daily 400-g
folic acid supplement plus natural diet; and 3) increased dietary folate intake to 400 g/day.
RESULTS At baseline, homocysteine was inversely related to plasma folate and was higher in TT
homozygotes. For the whole group, plasma folate increased by 46% after dietary folate and by
79% after supplementation, with reductions of homocysteine of 14% and 16%, respectively.
Within the genotype, TT homozygotes exhibited the most marked changes in these variables.
Brachial artery endothelial function, as determined by a change in end-diastolic diameter in
response to increased flow, was not changed by increased folate intake (98  73 m at
baseline, 110  69 m after a high-folate diet, 114  59 m after supplementation and
118  68 m after placebo). Plasma von Willebrand factor antigen was unaltered.
CONCLUSIONS Optimization of dietary folate or low-dose folic acid supplementation reduces plasma
homocysteine but does not enhance endothelial function, irrespective of the MTHFR
(C667T) genotype. (J Am Coll Cardiol 2001;38:1799–805) © 2001 by the American
College of Cardiology
Cardiovascular disease is associated with elevated plasma
homocysteine, but it has not been proven to have a causal
role (1,2). Major determinants of plasma homocysteine
concentration are dietary folate intake and genetic polymor-
phism in methylenetetrahydrofolate reductase (MTHFR)
(3–5). The most common genetic cause of moderate hyper-
homocysteinemia, occurring in homozygous form in 12%
of the Caucasian population, is MTHFR C677T mutation
(gene frequency 0.32) (6). Activity of MTHFR is re-
duced, and plasma homocysteine is typically elevated by
25% (7,8). The combination of TT genotype with re-
duced folate intake further elevates plasma homocysteine
(5).
It has been proposed that individuals with the TT
genotype are more likely to have vascular disease, particu-
larly in the context of suboptimal folate intake (9). How-
ever, a recent meta-analysis of MTHFR genotype studies
did not confirm this (10). Plasma homocysteine can be
lowered by folic acid supplements. Typical folate intake is
250 g/day in Britain, with a reference nutrient intake of
200 g/day. Increasing folate intake to 400 g/day achieves
near-maximal homocysteine reduction and has been pro-
posed as the optimal dietary folate intake (4). In the United
Kingdom, fortification with folic acid is not mandatory,
although there is an increasing trend for food manufacturers
to voluntarily fortify breakfast cereal and bread with it.
Women planning pregnancy are advised to take a daily
400-g folic acid supplement to reduce the incidence of
neural tube defects. In the United States, universal fortifi-
cation of grains with folic acid was introduced in 1998,
based on evidence that this would reduce the incidence of
neural tube defects, and with the additional suggestion that
it would improve cardiovascular health by reducing plasma
homocysteine (11).
The most plausible mechanism whereby homocysteine
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could cause vascular disease is by induction of endothelial
dysfunction (12). In a healthy artery, when blood flow is
increased, endothelial cells are stimulated to release nitric
oxide (NO), which induces vasodilation, a response termed
“flow-mediated dilation” (FMD). Impairment of FMD,
reflecting endothelial dysfunction, occurs with cardiovascu-
lar risk factors, including hypertension (13), smoking (14)
and diabetes (15). Endothelial damage may also be signified
by increased release of endothelial-derived proteins into the
plasma, such as von Willebrand factor (vWF) (16).
Endothelial dysfunction has been reported in homo-
cystinuria (17) and hyperhomocysteinemia (18,19). Our
group has reported that high-dose folic acid (5 mg/day)
enhances endothelial function in healthy subjects with mild
hyperhomocysteinemia (20).
The hypothesis to be tested was that increasing folate
intake by either optimization of dietary folate or low-dose
supplementation with folic acid would both lower homo-
cysteine and enhance endothelial function, the effect being
most marked in individuals with the TT genotype for
MTHFR. Endothelial function was assessed in a random-
ized, placebo-controlled intervention trial that recruited
subjects according to MTHFR genotype.
METHODS
Subject recruitment (Fig. 1). Healthy men and women
aged 18 to 65 years were recruited from blood donor
sessions and by workplace screening in South Wales. Ex-
clusion criteria were hypertension (diastolic 100 mm Hg),
diabetes, smoking, supplementation with folic acid and
vitamins B6 or B12 and pregnancy. The subjects provided
informed, written consent, and the study was approved by
the Local Research Ethics Committee (Bro Taf Health
Authority).
After completion of an eligibility questionnaire, suitable
volunteers (n  634) were screened for MTHFR (C677T)
genotype. Forty-two individuals with each genotype (CC,
CT and TT) entered the study.
Subject entry. Names (n  126) and randomization code,
but not MTHFR genotype, were relayed to the trial
coordinator, so that the study was double-blinded for geno-
type. Subjects were entered into the study over a period of 18
months. Subjects, as a whole group and as subgroups of 12,
were stratified for the MTHFR genotype and balanced for
intervention order. This avoided possible bias caused by enter-
ing individuals with the more common genotypes (CC and
CT) first and the less common genotype (TT) later.
Study design. The study was a cross-over study of Latin
square design incorporating three interventions each of
four months duration. After baseline assessment, the sub-
jects participated until completion of each of the three
interventions. Each visit was made at the same time of
day and followed an 8-h fast (except for water). The subjects
had a dietary assessment to estimate folate intake, pro-
vided a fasting blood sample and underwent assessment of
brachial artery endothelial function (FMD). Endothelium-
independent responses to nitrates were not assessed, to
maintain good compliance among the subjects. Dietary
advice was given as appropriate to the intervention.
Interventions. INTERVENTION 1: PLACEBO PHASE. The
subjects continued their usual diet, including foods contain-
ing natural folate, but excluding foods specifically fortified
with (synthetic) folic acid, and were provided with a
matched placebo so that intervention 1 could not be
distinguished from intervention 2. Folate intake was ex-
pected to be 200 g/day.
INTERVENTION 2: SUPPLEMENT PHASE. The subjects fol-
lowed the same diet as in intervention 1 and were provided
with a daily 400-g folic acid tablet. Total folate intake was
expected to be 600 g/day.
INTERVENTION 3: DIETARY FOLATE PHASE. The subjects
increased their dietary folate intake using both foods natu-
rally high in folate and folic acid–fortified foods available
Abbreviations and Acronyms
ANOVA  analysis of variance
FMD  flow-mediated dilation
MTHFR  methylenetetrahydrofolate reductase
NO  nitric oxide
vWF(Ag)  von Willebrand factor (antigen)
Figure 1. Flow chart detailing the volunteer recruitment procedure. After
determination of the methylenetetrahydrofolate reductase (MTHFR)
C677T genotype, equal numbers of subjects with each genotype (CC, CT
and TT) were allocated to the study.
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from general retail outlets (mainly breads and breakfast
cereals). The subjects were later reimbursed for the fortified
foods. The aim was to increase folate intake to 400
g/day.
The period of each intervention was four months. The
study was double-blinded for interventions 1 and 2. For
intervention 3, requiring a change of diet, the subjects and
nutritionist were aware of the intervention, but the vascular
scientist was not (i.e., single-blinded).
Dietary and compliance assessment. Full details of the
dietary methods will be reported elsewhere. In brief, at the
start of each intervention, the nutritionist provided advice
on the ensuing four-month period and explained the diet
diary and food-frequency questionnaire from which dietary
folate intake was estimated. Surplus tablets were collected to
monitor compliance.
Determination of the MTHFR (C677T) genotype. De-
oxyribonucleic acid was extracted from inner-cheek buccal
cells, collected using a cytobrush, and the genotype was
determined by heteroduplex analysis (3).
Blood analysis. Venous blood was centrifuged within
10 min of collection, and plasma was stored at 70°C. All
four samples from an individual were assayed in the same
batch to avoid inter-batch measurement imprecision. Total
homocysteine and folate were measured using Abbott IMX
methods (Abbott Diagnostics, Abbott Park, Illinois0. Von
Willebrand factor was assayed using an enzyme-linked
immunosorbent assay–based method.
Vascular protocol. Flow-mediated dilation was assessed in
the brachial artery (21). Brachial artery end-diastolic diam-
eter was measured using high-resolution (3 m) ultra-
sonic vessel wall tracking (Vadirec Medical Systems, Arn-
hem, Netherlands); blood flow was measured by continuous
wave Doppler imaging; and blood pressure was measured by
photoplethysmography (Finapres, Ohmeda, Madison, Wis-
consin). After baseline measurements, a wrist cuff was
inflated to suprasystolic blood pressure, distal to the point of
vascular measurement. Inflation of this cuff for 5 min
induced ischemia in the hand. Cuff release stimulated
reactive hyperemia in the hand, resulting in a secondary
increase in blood flow upstream along the brachial artery.
Blood flow and pressure and end-diastolic diameter were
recorded at 40-s intervals for 240 s after cuff release and at
6, 8 and 10 min until recovery to baseline values. The
maximal absolute change in end-diastolic diameter (m)
observed for each individual subject during the first 200 s
after cuff release was taken as the measure of FMD.
Vascular assessments were carried out by a trained vas-
cular research officer (C. H. P.) in a purposely built,
temperature-controlled room. Reproducibility studies car-
ried out on separate occasions in healthy subjects demon-
strated an inter-day coefficient of variation of 2.8% for
measurement of baseline diameter and 12.8% for measure-
ment of FMD.
Statistics. The primary analyses were those evaluating
differences in effect between the three intervention regi-
mens. Three-way analysis of variance (ANOVA) was per-
formed (SPSS, version 9.0), with models on subject, period
and treatment, and differences were made between pairs of
regimens derived. The interventions were tested against
baseline values by the paired t test. Confirmatory nonpara-
metric tests were used on account of skewed distributions.
All correlations reported are nonparametric (Spearman). A
p value 0.05 was considered significant.
RESULTS
Baseline characteristics (Table 1). Plasma folate and ho-
mocysteine were inversely related (rs  0.50, p  0.001)
for the whole group. Plasma folate and homocysteine levels
were very different (highly significant) between the three
genotypes by one-way ANOVA, with TT-genotype sub-
jects having the lowest and CC-genotype subjects having
the highest plasma folate levels (F  5.66, p  0.004 and
F  11.36, p  0.001, respectively), and CT-genotype
subjects having intermediate values, and vice versa for
homocysteine. Flow-mediated dilation was not related to
plasma folate (rs  0.044, p  0.62), homocysteine (rs 
0.018, p 0.84) or the MTHFR genotype (p 0.64). Von
Willebrand factor antigen (vWFAg) was not related to
plasma folate (rs  0.045, p  0.62), homocysteine (rs 
0.019, p  0.84) or the MTHFR genotype (p  0.23).
Flow-mediated dilation and vWFAg did not correlate with
each other (rs  0.052, p  0.51).
Effects of intervention (Tables 2 and 3). Three-way
ANOVA showed highly significant differences between the
three interventions in plasma folate (F  1.66, p  0.001)
and homocysteine (F  2.81, p  0.001), but not in FMD
(F  0.79, p  0.45) or plasma vWFAg (F  0.54, p 
0.58). In each case, there were highly significant differences
Table 1. Characteristics of Study Subjects at Baseline
Variable Mean  SD
Age at randomization (years) 39  12
Gender (male/female) 53/73
Systolic blood pressure (mm Hg) 118.4  15.4
Diastolic blood pressure (mm Hg) 69.8  11.1
Heart rate (beats/min) 63.4  8.9
Plasma folate (g/l) 7.8  3.4
Split by MTHFR genotype CC 9.1  3.5
CT 7.6  3.1
TT 6.7  3.3
Plasma total homocysteine (mol/l) 10.2  4.2
Split by MTHFR genotype CC 8.8  2.4
CT 9.3  2.5
TT 12.5  5.7
Flow-mediated dilation (m) 98  73
Split by MTHFR genotype CC 94  67
CT 93  68
TT 106  85
von Willebrand factor antigen (U/ml) 1.15  0.38
Split by MTHFR genotype CC 1.07  0.30
CT 1.16  0.41
TT 1.21  0.42
MTHFR  methylenetetrahydrofolate reductase.
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between subjects (p 0.001), but not between periods (p
0.1).
Folate and homocysteine. The expected values for folate
intake were achieved for each intervention. For the whole
group and relative to baseline, the dietary folate intervention
increased plasma folate by 46% (p  0.001) and reduced
homocysteine by 14% (p  0.001). The supplement inter-
vention increased plasma folate to a greater extent, by 79%
(p 0.001), but reduced homocysteine by a similar amount,
16%. After placebo, there was a trend toward reduced
plasma folate and increased homocysteine, but these were
not significant (p  0.37 and p  0.071, respectively).
For the whole group and after each intervention, plasma
folate and homocysteine were inversely related (rs  0.36
to 0.52, p  0.001). This inverse relationship was partic-
ularly marked for the TT-genotype subjects (rs  0.53 to
0.80, all p  0.002), who had the greatest changes
observed after the supplement intervention, where homo-
cysteine fell by 24%, compared with 8% in CC-genotype
subjects.
Vascular measurements. Flow-mediated dilation did not
differ significantly between the three interventions for any
MTHFR genotype (p  0.3). The time courses of the
vasodilatory response were similar after each intervention
(Fig. 2). Basal blood flow was similar throughout the study,
and peak flow was similar at each intervention (p  0.80).
Blood pressure and heart rate were similar to baseline values
throughout the study.
Table 2. Biochemical and Hemodynamic Variables at Baseline and After Each Intervention for the Study Group as a Whole
Baseline
Intervention
Placebo Diet Supplement
Nutritional data
Folate intake (g/day) 254  83 221  88 468  133 561  98
Biochemical data
Folate (g/l) 7.8  3.4 7.6  3.2 11.4  3.7 14.0  7.3
Homocysteine (mol/l) 10.2  4.2 10.9  6.9 8.7  3.3 8.5  3.1
vWFAg (U/ml) 1.15  0.38 1.14  0.43 1.12  0.44 1.13  0.40
Hemodynamic data
Systolic BP (mm Hg) 118.4  15.4 120.5  15.9 120.5  14.3 119.3  13.6
Diastolic BP (mm Hg) 69.8  11.1 67.6  10.8 67.6  10.4 68.0  11.8
Heart rate (beats/min) 63.4  8.9 64.0  9.5 62.1  9.1 62.7  9.0
Brachial artery data
Baseline diameter (mm) 3.60  0.68 3.61  0.67 3.61  0.67 3.59  0.69
FMD (m) 98  73 118  68 110  67 114  59
Basal blood flow (ml/min) 32  26 42  39 36  33 37  37
Peak blood flow (ml/min) 152  90 155  90 157  106 155  106
Data are presented as the mean value  SD.
BP  blood pressure; FMD  flow-mediated dilation, as measured by maximal change in end-diastolic diameter of the brachial artery in response to increased blood flow;
vWFAg  von Willebrand Factor antigen.
Table 3. Biochemical and Vascular Variables at Baseline and After Each Intervention*
Baseline
Intervention
Placebo Diet Supplement
Plasma folate (g/l)
CC 9.1  3.5 8.4  3.1 12.1  3.6 16.2  11.1
CT 7.6  3.1 7.8  3.0 11.0  3.7 13.3  3.7
TT 6.7  3.3 6.5  3.2 10.9  3.8 12.3  3.8
Homocysteine (mol/l)
CC 8.8  2.4 8.9  2.4 7.9  2.6 8.1  2.7
CT 9.3  2.5 9.3  2.0 8.2  1.6 8.1  1.5
TT 12.5  5.7 14.5  10.9 10.2  4.7 9.5  4.3
vWFAg (U/ml)
CC 1.07  0.30 1.14  0.41 1.04  0.38 1.07  0.32
CT 1.16  0.41 1.09  0.48 1.06  0.33 1.15  0.42
TT 1.21  0.42 1.20  0.40 1.27  0.56 1.17  0.46
FMD (m)
CC 94  68 113  66 110  69 117  55
CT 93  68 123  81 96  69 111  64
TT 106  85 117  58 123  61 115  60
*The study group was split by the methylenetetrahydrofolate reductase C677T genotype (CC, CT or TT). Data are presented
as the mean value  SD.
Abbreviations as in Table 2.
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DISCUSSION
This study demonstrates that in healthy individuals, opti-
mization of dietary folate intake or supplementation with
low-dose folic acid lowers plasma homocysteine but does
not enhance vascular endothelial function, as assessed by
FMD or plasma vWFAg.
Folate and homocysteine responses. This study showed
that subjects homozygous for the MTHFR C677T muta-
tion had the highest homocysteine concentrations and had
the greatest reductions in homocysteine with folate; how-
ever, despite this, they did not demonstrate any changes in
endothelial response.
Endothelial function. The lack of any change in FMD or
vWFAg is evidence against mild hyperhomocysteinemia
causing endothelial dysfunction in healthy individuals, sug-
gesting that low-dose folate may not be beneficial in
preventing vascular disease in the general population.
One possible explanation of the failure to show any
change in FMD is that measurement variabilities may
obscure a small change. However, particular care was
taken to minimize measurement errors in the vascular
technique. All assessments were made in a purposely built,
temperature-controlled laboratory by the same trained sci-
entist, using the same equipment throughout.
Rapid on-line data acquisition enabled construction of a
time course of FMD responses (Fig. 2). This provides a
more complete picture of the vascular response, as opposed
to just a single measurement of maximal artery diameter
taken between 1 and 2 min after cuff release, as is usually
done. The time courses of FMD are similar after each
intervention.
To ensure complete objectivity, careful attention was
given to the study design. The balanced cross-over study
design avoids inter-subject variation, thus facilitating detec-
tion of small changes in vascular function. The study was
placebo-controlled, and all vascular measurements were
carried out in a blinded manner (i.e., the vascular scientist
was unaware of the MTHFR genotype or intervention).
An effect of folate could have been missed if the number
of study subjects was too small. However, a sample size of
126 is a large number for a study of this nature. Stratifica-
tion by MTHFR genotype ensured that one-third of the
subjects had the TT genotype (compared with 12% of the
general population); this subgroup was expected to have the
greatest response to folate. The absence of a trend for
increased FMD within this subgroup suggests that the
“negative” result was not caused by inadequate numbers.
Poor compliance with the interventions can be dis-
counted because plasma folate and homocysteine responded
as expected.
Thus, we are unable to identify any aspect in the study
design or procedure that would explain the negative result, and
we must therefore consider other physiologic interpretations.
Homocysteine and cardiovascular risk. Some studies sug-
gest that homocysteine may only exert an effect on vascular
risk in synergy with other risk factors (22,23). Subjects
recruited for this study had no other cardiovascular risk
factors. Our findings suggest that in the absence of other
risk factors, mild hyperhomocysteinemia and low-dose folic
acid supplementation may have no physiologic vascular
significance.
Folate dose and mechanisms. Several studies have re-
ported beneficial endothelial effects of high-dose folic acid
(20,24). We have previously reported that folic acid, at
5,000 g/day, improves FMD in individuals with mild
hyperhomocysteinemia but with no known cardiovascular
risk factors (20). In that study, plasma homocysteine was
13.6 mol/l, which is similar to that of the TT-genotype
Figure 2. Time course of brachial artery response to increased blood flow at baseline and after each intervention for the group as a whole. Data are given
as the change in brachial artery end-diastolic diameter (mean  SEM). Open squares  baseline; solid upward triangles  placebo; solid downward
triangles  diet; and open diamonds  supplement.
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subjects in this study (14.5 mol/l). However, the dose of
folic acid used by Bellamy et al. (20) was pharmacologic
(5,000 g/day), which is in contrast to the physiologic dose
of 400 g/day used in our study. Daily supplementation
with 500 g to 5 mg of folic acid produces similar
homocysteine-lowering effects, consistent with a plateau
effect with doses of folic acid 400 g/day (4). The
homocysteine-lowering effects of these low- and high-dose
folic acid interventions are approximately equivalent, so that
the discrepancy in results cannot be explained by differences
in the degree of homocysteine lowering. High-dose folic
acid may therefore be exerting its effects by a mechanism
independent of homocysteine lowering.
Other studies have reported effects of high-dose folic acid
on endothelial function, independent of homocysteine low-
ering. Methionine loading, which rapidly elevates plasma
homocysteine, has been shown to impair flow-mediated
vasodilation (25,26). Concomitant administration of high-
dose folic acid (5 to 20 mg orally) prevents this effect
without immediately affecting plasma homocysteine
(27,28). In individuals with familial hypercholesterolemia
but normal homocysteine levels, endothelial dysfunction can
be restored by both infusion of 5-methyltetrahydrofolate
(29) and high-dose oral folic acid (30). Mechanisms
whereby folic acid could act directly include modification of
cellular oxidative metabolism to increase the availability of
tetrahydrobiopterin, a co-factor for NO synthase. Folic acid
has a twofold effect on NO synthase in vitro, both reducing
superoxide production and enhancing NO synthesis (31).
It could be argued that the brachial artery does not
accurately represent vascular beds in which clinically impor-
tant atherosclerosis occurs. However, most systemic or
circulatory cardiovascular risk factors induce generalized
endothelial dysfunction, and interventions to correct these
risk factors improve endothelial function. Peripheral artery
NO-mediated responses appear to be a valid surrogate
marker of coronary function (32), and recent studies have
demonstrated that coronary endothelial dysfunction is a
long-term predictor of the development of atherosclerosis
and cardiac events (33,34).
This study does not support the proposal that mild
elevation of plasma homocysteine in healthy individuals is a
causal agent for cardiovascular disease. However, before
definitive conclusions can be reached, long-term, large-scale
interventional studies assessing the effects of folic acid
supplementation in vascular disease are needed. There is still
an important requirement for clinical trials to be carried out in
high-risk populations, with monitoring of clinical events (35).
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